AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
15 Sep 2023 03:00 PM
RNS
Enhertu recommended in EU for HER2-mutant NSCLC
11 Sep 2023 04:00 PM
RNS
Fasenra Phase III EGPA trial met primary endpoint
06 Sep 2023 07:00 AM
RNS
Update on US review of Ultomiris for NMOSD
01 Sep 2023 03:00 PM
RNS
Total Voting Rights
01 Aug 2023 03:00 PM
RNS
Total Voting Rights
28 Jul 2023 07:05 AM
RNS
Alexion enters gene therapy agreement with Pfizer
28 Jul 2023 07:00 AM
RNS
Half-year Report
17 Jul 2023 06:10 PM
RNS
Beyfortus approved in US for infant RSV prevention
03 Jul 2023 03:00 PM
RNS
Total Voting Rights
03 Jul 2023 07:00 AM
RNS
Dato-DXd significantly improved PFS in lung cancer
09 Jun 2023 07:05 AM
RNS
nirsevimab recommended for infant RSV protection
09 Jun 2023 07:00 AM
RNS
AstraZeneca agreement with Quell Therapeutics
02 Jun 2023 05:00 PM
RNS
Imfinzi improved pCR in gastric and GEJ cancers
01 Jun 2023 03:05 PM
RNS
Block listing Interim Review
01 Jun 2023 03:00 PM
RNS
Total Voting Rights
01 Jun 2023 07:00 AM
RNS
Lynparza approved in US for BRCAm prostate cancer
26 May 2023 07:00 AM
RNS
Imfinzi + Lynparza prolonged PFS in endometrial ca
22 May 2023 07:05 AM
RNS
Directorate Change
17 May 2023 07:00 AM
RNS
Tagrisso plus chemo improved PFS in lung cancer
09 May 2023 11:00 AM
RNS
Director/PDMR Shareholding
09 May 2023 07:00 AM
RNS
Farxiga extended in the US for heart failure
02 May 2023 03:00 PM
RNS
Total Voting Rights
02 May 2023 10:00 AM
RNS
Director/PDMR Shareholding
02 May 2023 07:00 AM
RNS
ODAC vote on Lynparza combo in prostate cancer
27 Apr 2023 05:30 PM
RNS
Result of AGM
27 Apr 2023 07:05 AM
RNS
Board Committee Changes
27 Apr 2023 07:00 AM
RNS
1st Quarter Results
26 Apr 2023 04:45 PM
RNS
Director Declaration
11 Apr 2023 07:00 AM
RNS
Update to arrangements with Sobi and Sanofi
05 Apr 2023 07:00 AM
RNS
Lynparza + Imfinzi met endpoint in ovarian cancer
03 Apr 2023 03:00 PM
RNS
Total Voting Rights
03 Apr 2023 07:00 AM
RNS
Ultomiris recommended for NMOSD EU approval
30 Mar 2023 07:00 AM
RNS
AstraZeneca completes KYM agreement for CMG901
27 Mar 2023 11:00 AM
RNS
Director/PDMR Shareholding
22 Mar 2023 11:00 AM
RNS
Notice of AGM
09 Mar 2023 07:00 AM
RNS
Imfinzi improved EFS in resectable lung cancer
08 Mar 2023 11:01 AM
RNS
Director/PDMR Shareholding
08 Mar 2023 11:00 AM
RNS
Director/PDMR Shareholding
06 Mar 2023 07:00 AM
RNS
Enhertu DESTINY-PanTumor02 shows positive results
01 Mar 2023 03:00 PM
RNS
Total Voting Rights
01 Mar 2023 07:00 AM
RNS
AstraZeneca prices a $2.25bn bond offering
24 Feb 2023 06:15 PM
RNS
AstraZeneca prices a EUR1.5bn bond offering
24 Feb 2023 02:05 PM
RNS
AstraZeneca acquires CinCor for cardiorenal asset
24 Feb 2023 11:00 AM
RNS
Director/PDMR Shareholding
23 Feb 2023 07:00 AM
RNS
AstraZeneca enters agreement with KYM for CMG901
22 Feb 2023 07:10 AM
RNS
Filing of Form 20-F with SEC
21 Feb 2023 11:00 AM
RNS
Annual Financial Report
13 Feb 2023 02:01 PM
RNS
Director/PDMR Shareholding
13 Feb 2023 02:00 PM
RNS
Director/PDMR Shareholding
09 Feb 2023 07:00 AM
RNS
Final Results
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings